Analystreport

BioXcel Therapeutics (BTAI) is now covered by Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.

BioXcel Therapeutics, Inc.  (BTAI) 
Last bioxcel therapeutics, inc. earnings: 11/14 07:00 am Check Earnings Report